INVO Fertility (NASDAQ:IVF) Stock Price Down 0.7% – Here’s What Happened

INVO Fertility, Inc (NASDAQ:IVF) was down 0.7% on Friday . The company traded as low as $1.39 and last traded at $1.48. Approximately 44,432 shares were traded during trading, a decline of 94% from the average daily volume of 796,319 shares. The stock had previously closed at $1.49.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on IVF shares. Weiss Ratings raised INVO Fertility from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Wall Street Zen raised INVO Fertility from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

INVO Fertility Stock Down 0.7%

The company has a quick ratio of 0.25, a current ratio of 0.27 and a debt-to-equity ratio of 0.15. The business has a fifty day simple moving average of $1.83 and a two-hundred day simple moving average of $4.17. The company has a market capitalization of $2.65 million, a price-to-earnings ratio of 0.00 and a beta of 2.33.

INVO Fertility (NASDAQ:IVF) last released its quarterly earnings data on Tuesday, June 2nd. The company reported $472.78 earnings per share for the quarter. The company had revenue of $1.60 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in INVO Fertility stock. Armistice Capital LLC acquired a new position in INVO Fertility, Inc (NASDAQ:IVF) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 207,644 shares of the company’s stock, valued at approximately $156,000. Armistice Capital LLC owned approximately 8.69% of INVO Fertility as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 12.02% of the company’s stock.

About INVO Fertility

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.